ARC-520: Preliminary Phase I data

Preliminary data from a double-blind, placebo-controlled, Australian Phase I trial in 36 healthy volunteers showed that single doses of 0.01, 0.1, 0.3, 0.6, 1.2 and 2 mg/kg IV ARC-520 were well tolera...